Abstract
Increasing less common ALK gene fusion that results in overexpression of the kinase domain of the anaplastic lymphoma tyrosine kinase receptor (ALK) protein is reported recently due to the development of next-generation sequencing (NGS). Individual responses to therapeutic ALK inhibitors became topical issues. Patient-derived organoids (PDOs) created from lung adenocarcinomas (LADCs) can be used for the establishment of preclinical models that can recapitulate multiple features of the original tumors and enable the determination of drug sensitivity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
